Overview

• Cancer diagnostics firm's Q4 revenue rose 11% yr/yr, driven by higher-value tests

• Adjusted EPS for Q4 beat analyst expectations

• Company successfully resolved RaDaR ST patent litigation

Outlook

• NeoGenomics expects 2026 revenue between $793 mln and $801 mln

• Company anticipates 2026 net loss between $63 mln and $50 mln

• NeoGenomics sees modest MRD revenue contribution in 2026, substantial growth in 2027

Result Drivers

• HIGHER VALUE TESTS - NeoGenomics attributed Q4 revenue growth to a shift towards higher-value tests, including NGS, and strategic reimbursement initiatives

• NGS GROWTH - NGS grew 23% in Q4, significantly ahead of market growth, driven by innovation in the community channel

• PATHLINE ACQUISITION - Revenue growth was supported by contributions from the Pathline acquisition, despite lower non-clinical revenue

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted EPS	Beat	$0.06	$0.04 (13 Analysts)
Q4 Adjusted Net Income		$8 mln
Q4 Net Income		-$10 mln
Q4 Adjusted EBITDA		$13 mln
Q4 Gross Profit		$83 mln
Q4 Operating Expenses		$97 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for Neogenomics Inc is $14.00, about 23% above its February 13 closing price of $11.38

• The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 63 three months ago

Press Release: ID:nBw3MNlc4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.